NanoVibronix Adjourns Special Meeting of Stockholders
March 31 2021 - 6:50PM
Business Wire
NanoVibronix, Inc. (the “Company”) (NASDAQ:
NAOV) announced today that the Company’s Special Meeting of
Stockholders, scheduled for 10:00 a.m. Eastern time today, March
31, 2021, has been adjourned to allow for more time for
stockholders to vote. The meeting has been scheduled to reconvene
on April 14, 2021 at 10:00 a.m. Eastern time and will be held
virtually online at
www.virtualshareholdermeeting.com/NAOV2021SM.
During the period of the adjournment, the Company will continue
to solicit proxies from its stockholders with respect to the
proposals set forth in the Company’s proxy statement. Proxies
previously submitted in respect to the Special Meeting will be
voted at the reconvened meeting unless properly revoked.
The Company encourages all stockholders who have not yet
voted to do so before April 13, 2021 at 11:59 p.m. Eastern time.
The stockholders may vote by internet at www.proxyvote.com, or by
telephone at 1-800-690-6903 for stockholders of record and
1-800-454-8683 for beneficial stockholders, or by returning a
properly executed proxy card to Vote Processing, c/o Broadridge, 51
Mercedes Way, Edgewood, NY 11717.
If you have any questions, need additional material, or need
assistance in voting your shares, please feel free to contact the
firm assisting the Company in the solicitation of proxies,
Kingsdale Advisors. Brokers, banks and other nominees may call
416-867-2272. Stockholders may call toll-free 1-877-657-5856. Or
you may contact Kingsdale Advisors by email at
contactus@kingsdaleadvisors.com.
About NanoVibronix
NanoVibronix Inc. (NASDAQ: NAOV) is a medical device company
headquartered in Elmsford, New York, with research and development
in Nesher, Israel, which is focused on developing medical devices
utilizing its proprietary and patented low intensity surface
acoustic wave (SAW) technology. This technology allows for the
creation of low-frequency ultrasound waves that can be utilized for
a variety of medical applications, including the disruption of
biofilms and bacteria colonization, as well as providing pain
relief. The devices can be administered at home without the
assistance of medical professionals. The Company’s primary products
include PainShield®, UroShield™ and WoundShield™. Additional
information about the Company is available at:
www.nanovibronix.com.
Additional Information and where to find it
The Company has filed a definitive proxy statement and
associated proxy card with the U.S. Securities and Exchange
Commission (the “SEC”) in connection with the solicitation of
proxies for the Special Meeting of Stockholders of the Company (the
“Special Meeting”) on March 31, 2021. The Company, its directors,
its executive officers and certain other individuals set forth in
the definitive proxy statement will be deemed participants in the
solicitation of proxies from shareholders in respect of the Special
Meeting. Information regarding the names of the Company’s directors
and executive officers and certain other individuals and their
respective interests in the Company by security holdings or
otherwise are set forth in the definitive proxy statement filed
with the SEC on March 3, 2021. BEFORE MAKING ANY VOTING DECISION,
STOCKHOLDERS OF THE COMPANY ARE URGED TO READ ALL RELEVANT
DOCUMENTS FILED WITH OR FURNISHED TO THE SEC, INCLUDING THE
DEFINITIVE PROXY STATEMENT AND ANY SUPPLEMENTS THERETO AND
ACCOMPANYING PROXY CARD, BECAUSE THEY CONTAIN IMPORTANT
INFORMATION. Investors and shareholders can obtain a copy of the
documents filed by the Company with the SEC, including the
definitive proxy statement, free of charge by visiting the SEC’s
website, www.sec.gov. The Company’s stockholders can also obtain,
without charge, a copy of the definitive proxy statement and other
relevant filed documents when available from the Company’s website
at https://ir.nanovibronix.com/sec-filings.
Forward-looking Statements
This press release contains “forward-looking statements.” Such
statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,”
“estimates,” “aims,” “believes,” “hopes,” “potential” or similar
words. Forward-looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company’s control, and cannot be predicted or
quantified and consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements.
Such risks and uncertainties include, without limitation, risks and
uncertainties associated with (i) market acceptance of our existing
and new products or lengthy product delays in key markets; (ii)
negative or unreliable clinical trial results (iii) an inability to
secure regulatory approvals for the sale of our products, (iv)
intense competition in the medical device industry from much
larger, multinational companies, (v) product liability claims, (vi)
product malfunctions, (vii) our limited manufacturing capabilities
and reliance on subcontractors for assistance, (viii) insufficient
or inadequate reimbursement by governmental and other third party
payers for our products, (ix) our efforts to successfully obtain
and maintain intellectual property protection covering our
products, which may not be successful, (x) legislative or
regulatory reform of the healthcare system in both the U.S. and
foreign jurisdictions, (xi) our reliance on single suppliers for
certain product components, (xii) the fact that we will need to
raise additional capital to meet our business requirements in the
future and that such capital may not be available, or may be
costly, dilutive or difficult to obtain and (xiii) the fact that we
conduct business in multiple foreign jurisdictions, exposing us to
foreign currency exchange rate fluctuations, logistical and
communications challenges, burdens and costs of compliance with
foreign laws and political and economic instability in each
jurisdiction. More detailed information about the Company and the
risk factors that may affect the realization of forward looking
statements is set forth in the Company’s filings with the
Securities and Exchange Commission (SEC), including the Company’s
Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q.
Investors and security holders are urged to read these documents
free of charge on the SEC’s web site at http://www.sec.gov. The
Company assumes no obligation to publicly update or revise its
forward-looking statements as a result of new information, future
events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210331006033/en/
Investor Contacts:
NanoVibronix, Inc. bmurphy@nanovibronix.com (630) 338-5022
Or:
Brett Maas, Managing Principal, Hayden IR, LLC
brett@haydenir.com (646) 536-7331
NanoVibronix (NASDAQ:NAOV)
Historical Stock Chart
From May 2024 to Jun 2024
NanoVibronix (NASDAQ:NAOV)
Historical Stock Chart
From Jun 2023 to Jun 2024